The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
HOME > BUSINESS
BUSINESS
- Japan Drug Makers Should Consider Mergers, Other Deals to Survive: Chugai Chief
July 27, 2015
- Toho to Narrow Down Recommended Drug Makers, Will Need to Devise Specific Marketing Policy for Generics: Pres. Edahiro
July 27, 2015
- Fujifilm, Kyowa Kirin JV to Develop Avastin Biosimilar with AZ
July 27, 2015
- Kyowa Kirin Ups Earnings Outlook on Nesp, G-Lasta
July 27, 2015
- Sumitomo Dainippon, Kyoto Univ., Hitachi to Collaborate on Regenerative Medicine for Parkinson’s Disease Utilizing iPS Cells
July 27, 2015
- Chugai Revenues Up 8.2% on Cancer Drugs, Actemra
July 24, 2015
- Toho to Differentiate Itself through Customer Support Rather than Prices: Pres.
July 24, 2015
- Astellas, AIST Partner Up for Joint Research for IT Drug-Discovery Technologies
July 24, 2015
- Kyowa Kirin to File for Regulatory Approval of Psoriasis Treatment Brodalumab
July 24, 2015
- EU Approves Opdivo for Squamous NSCLC: BMS
July 23, 2015
- Cell Transplantation Using iPS Cell-Derived Renal Progenitors Effective for Acute Kidney Injury in Mice: Kyoto Univ., Astellas
July 23, 2015
- PIII Study of Opdivo in Renal Cell Carcinoma Ends Early Based on Favorable Results: Ono, BMS
July 23, 2015
- JCR, Eisai Collaborate for Blood-Brain Barrier Penetration Technology
July 22, 2015
- Ono Files Opdivo for Non-Squamous NSCLC
July 22, 2015
- Japanese Contract Manufacturing Market Grows to 290 Billion Yen in FY2013: Yano Research
July 21, 2015
- Eisai to Transfer US Subsidiary Plant to Biogen
July 21, 2015
- GSK, Pola Pharma Join Hands for Marketing of Acne Vulgaris Treatment Duac
July 21, 2015
- Kyowa Kirin R&D Exec Lauds Sakigake System, but Calls for More Incentives
July 17, 2015
- Deltyba Effective in Extensively Drug-Resistant Tuberculosis: Otsuka
July 17, 2015
- Kyowa Kirin Grants AZ Option Rights to Commercialization of Benralizumab in Japan
July 17, 2015
ページ
PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…